Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03628131 : Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
PhasePhase 1/Phase 2
AgesMin: 2 Years Max: 22 Years
Inclusion Criteria:

- Patients with refractory/relapsed solid tumor (Stable or progressive disease after
1st-line treatment or relapse)

- Patients previously enrolled to "Genomic diagnosis of pediatric tumors by NGS (IRB No.
SMC 2015-11-053)"

Exclusion Criteria:

- Patients who had high-dose chemotherapy and autologous stem cell transplantation

- Patients with organ dysfunction as follows (creatinine elevation = 1.5 x upper limit
of normal (ULN), ejection fraction <40%, significant arrhythmia or conduction

- Patients who are not eligible to have scheduled treatment due to the other significant
impaired organ function

- Patients with active bleeding

- Patients who are taking strong CYP3A4 inhibitors, QTc-prolonging drugs, antithrombotic
agents, or anti-platelet agents

- Pregnant or nursing women

- Patients who can not swallow the pill
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557